药学学报, 2016, 51(10): 1505-1512
引用本文:
刘雯, 郭文洁, 徐强, 孙洋. NLRP3炎症小体调控机制研究进展[J]. 药学学报, 2016, 51(10): 1505-1512.
LIU Wen, GUO Wen-jie, XU Qiang, SUN Yang. Advances in mechanisms for NLRP3 inflammasomes regulation[J]. Acta Pharmaceutica Sinica, 2016, 51(10): 1505-1512.

NLRP3炎症小体调控机制研究进展
刘雯, 郭文洁, 徐强, 孙洋
南京大学生命科学学院, 医药生物技术国家重点实验室, 江苏 南京 210023
摘要:
炎症小体活化是由多蛋白复合物组装信号介导的炎症相关的半胱氨酸天冬氨酸特异蛋白酶(caspase)活化以及白细胞介素-1(interleukin-1β,IL-1β)、白细胞介素-18(interleukin-18,IL-18)等炎症因子的成熟过程。其中NOD(nucleotide binding oligomerization domain)样受体家族3(NOD-like receptors,NLRP3)炎症小体是目前研究最透彻的炎症小体类型,它参与了人类众多疾病的发生发展。因此靶向NLRP3炎症小体已经成为相关疾病治疗药物开发的热点。本综述总结了近5年来关于NLRP3炎症小体的研究进展,包括NLRP3 priming阶段的调控、蛋白复合物组装的调控、内源性代谢物质及亚细胞器对NLRP3的活化调节及小分子抑制剂的研究。对NLRP3调控机制的深入认识将有助于新药物靶标发现和治疗药物的开发。
关键词:    炎性疾病      NLRP3炎症小体      白介素-1β      调控     
Advances in mechanisms for NLRP3 inflammasomes regulation
LIU Wen, GUO Wen-jie, XU Qiang, SUN Yang
State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing 210023, China
Abstract:
Activation of inflammasomes involves multi-protein assembly and activation of inflammatory caspase and maturation of pro-inflammatory cytokines interleukin-1β (IL-1β) and interleukin-18 (IL-18). Among those types of inflammasomes, NOD (nucleotide binding oligomerization domain)-like receptors (NLRP3) is the most studied inflammasome which involves in amount of human inflammatory and autoimmune diseases. Therefore, targeting on NLRP3 inflammasome has been one of the promising methods for treatment of diseases. In this review, we focused on the studies in the latest five years on the mechanisms of NLRP3 inflammasome regulation which mainly including NLRP3 priming, three protein complex assembly and regulation of NLRP3 inflammasome activation by endogenous metabolic compounds, iron flux, subcellular structure, other types of cells and small molecular compounds. Better understanding of NLRP3 inflammasome will be benefit for potential drug target and treatment of NLRP3 inflammasome-associated diseases.
Key words:    inflammatary disease    NLRP3 inflammasome    interleukin-1β    regulation   
收稿日期: 2016-04-22
DOI: 10.16438/j.0513-4870.2016-0380
基金项目: 国家自然科学基金优秀青年基金项目(81422050);国家自然科学基金重大研究计划培育项目(91229109).
通讯作者: 孙洋
Email: yangsun@nju.edu.cn
相关功能
PDF(1395KB) Free
打印本文
0
作者相关文章
刘雯  在本刊中的所有文章
郭文洁  在本刊中的所有文章
徐强  在本刊中的所有文章
孙洋  在本刊中的所有文章

参考文献:
[1] Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes[J]. Nat Rev Immunol, 2013, 13:397-411.
[2] Shi J, Zhao Y, Wang K, et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death[J]. Nature, 2015, 526:660-665.
[3] Viganò E, Diamond CE, Spreafico R, et al. Human cas-pase-4 and caspase-5 regulate the one-step non-canonical inflammasome activation in monocytes[J]. Nat Commun, 2015, 6:8761.
[4] Qiao Y, Wang P, Qi JN, et al. TLR-induced NF-κB acti-vation regulates NLRP3 expression in murine macrophages[J]. FEBS Lett, 2012, 586:1022-1026.
[5] Ng GZ, Menheniott TR, Every AL, et al. The MUC1 mucin protects against Helicobacter pylori pathogenesis in mice by regulation of the NLRP3 inflammasome[J]. Gut, 2016, 65:1087-1099.
[6] Lin KM, Hu W, Troutman TD, et al. IRAK-1 bypasses priming and directly links TLRs to rapid NLRP3 inflam-masome activation[J]. Proc Natl Acad Sci U S A, 2014, 111:775-780.
[7] Vande Walle L, Van Opdenbosch N, Jacques P, et al. Nega-tive regulation of the NLRP3 inflammasome by A20 protects against arthritis[J]. Nature, 2014, 512:69-73.
[8] Duong BH, Onizawa M, Oses-Prieto JA, et al. A20 re-stricts ubiquitination of pro-interleukin-1β protein complexes and suppresses NLRP3 inflammasome activity[J]. Immunity, 2015, 42:55-67.
[9] Kischkel FC, Lawrence DA, Chuntharapai A, et al. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5[J]. Immunity, 2000, 12:611-620.
[10] Lee P, Lee DJ, Chan C, et al. Dynamic expression of epidermal caspase 8 simulates a wound healing response[J]. Nature, 2009, 458:519-523.
[11] Gurung P, Anand PK, Malireddi RK, et al. FADD and caspase-8 mediate priming and activation of the canonical and noncanonical Nlrp3 inflammasomes[J]. J Immunol, 2014, 192:1835-1846.
[12] Kang S, Fernandes-Alnemri T, Rogers C, et al. Caspase-8 scaffolding function and MLKL regulate NLRP3 inflam-masome activation downstream of TLR3[J]. Nat Commun, 2015, 6:7515.
[13] Kang TB, Yang SH, Toth B, et al. Caspase-8 blocks kinase RIPK3-mediated activation of the NLRP3 inflammasome[J]. Immunity, 2013, 38:27-40.
[14] Huai WW, Zhao R, Song H, et al. Aryl hydrocarbon receptor negatively regulates NLRP3 inflammasome activity by inhibiting NLRP3 transcription[J]. Nat Commun, 2014, 5:4738.
[15] Bauernfeind F, Rieger A, Schildberg FA, et al. NLRP3 inflammasome activity is negatively controlled by miR-223[J]. J Immunol, 2012, 189:4175-4181.
[16] Haneklaus M, Gerlic M, Kurowska-Stolarska M, et al. Cutting edge:miR-223 and EBV miR-BART15 regulate the NLRP3 inflammasome and IL-1β production[J]. J Immunol, 2012, 189:3795-3799.
[17] Fan Z, Lu M, Qiao C, et al. MicroRNA-7 enhances subven-tricular zone neurogenesis by inhibiting NLRP3/caspase-1 axis in adult neural stem cells[J]. Mol Neurobiol, 2015. DOI:10.1007/s12035-015-9620-5.
[18] Chen S, Smith BAH, Iype J, et al. MicroRNA-155-deficient dendritic cells cause less severe GVHD through reduced migration and defective inflammasome activation[J]. Blood, 2015, 126:103-112.
[19] Juliana C, Fernandes-Alnemri T, Kang S, et al. Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation[J]. J Biol Chem, 2012, 287:36617-36622.
[20] Py BF, Kim MS, Vakifahmetoglu-Norberg H, et al. Deubiqui-tination of NLRP3 by BRCC3 critically regulates inflam-masome activity[J]. Mol Cell, 2013, 49:331-338.
[21] Stehlik C, Dorfleutner A. COPs and POPs:modulators of inflammasome activity[J]. J Immunol, 2007, 179:7993-7998.
[22] de Almeida L, Khare S, Misharin AV, et al. The PYRIN domain-only protein POP1 inhibits inflammasome assembly and ameliorates inflammatory disease[J]. Immunity, 2015, 43:264-276.
[23] Le HT, Harton JA. Pyrin-and CARD-only proteins as regulators of NLR functions[J]. Front Immunol, 2013, 4:275.
[24] Matusiak M, Van Opdenbosch N, Lamkanfi M. CARD-and pyrin-only proteins regulating inflammasome activation and immunity[J]. Immunol Rev, 2015, 265:217-230.
[25] Wang YT, Hasegawa M, Imamura R, et al. PYNOD, a novel Apaf-1/CED4-like protein is an inhibitor of ASC and caspase-1[J]. Int Immunol, 2004, 16:777-786.
[26] Jin J, Yu Q, Han CF, et al. LRRFIP2 negatively regulates NLRP3 inflammasome activation in macrophages by promoting Flightless-I-mediated caspase-1 inhibition[J]. Nat Commun, 2013, 4:2075.
[27] Martin BN, Wang CH, Willette-Brown J, et al. IKKα negatively regulates ASC-dependent inflammasome activa-tion[J]. Nat Commun, 2014, 5:4977.
[28] Yang CS, Kim JJ, Kim TS, et al. Small heterodimer partner interacts with NLRP3 and negatively regulates activation of the NLRP3 inflammasome[J]. Nat Commun, 2015, 6:6115.
[29] Wu YH, Kuo WC, Wu YJ, et al. Participation of c-FLIP in NLRP3 and AIM2 inflammasome activation[J]. Cell Death Differ, 2014, 21:451-461.
[30] Yan YQ, Jiang W, Liu L, et al. Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome[J]. Cell, 2015, 160:62-73.
[31] Yan YQ, Jiang W, Spinetti T, et al. Omega-3 fatty acids prevent inflammation and metabolic disorder through inhibition of NLRP3 inflammasome activation[J]. Immunity, 2013, 38:1154-1163.
[32] Youm YH, Nguyen KY, Grant RW, et al. The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease[J]. Nat Med, 2015, 21:263-269.
[33] Mao KR, Chen SZ, Chen MK, et al. Nitric oxide suppresses NLRP3 inflammasome activation and protects against LPS-induced septic shock[J]. Cell Res, 2013, 23:201-212.
[34] Yu N, Liu S, Yi X, et al. Serum amyloid A induces inter-leukin-1β secretion from keratinocytes via the NACHT, LRR and PYD domains-containing protein 3 inflammasome[J]. Clin Exp Immunol, 2015, 179:344-353.
[35] Guarda G, Braun M, Staehli F, et al. Type I interferon inhibits interleukin-1 production and inflammasome activation[J]. Immunity, 2011, 34:213-223.
[36] Zhou RB, Tardivel A, Thorens B, et al. Thiore-doxin-interacting protein links oxidative stress to inflammasome activation[J]. Nat Immunol, 2010, 11:136-140.
[37] Schroder K, Zhou RB, Tschopp J. The NLRP3 inflam-masome:a sensor for metabolic danger?[J]. Science, 2010, 327:296-300.
[38] Hui STY, Andres AM, Miller AK, et al. Txnip balances metabolic and growth signaling via PTEN disulfide reduction[J]. Proc Natl Acad Sci U S A, 2008, 105:3921-3926.
[39] Pétrilli V, Papin S, Dostert C, et al. Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration[J]. Cell Death Differ, 2007, 14:1583-1589.
[40] Rivers-Auty J, Brough D. Potassium efflux fires the canon:potassium efflux as a common trigger for canonical and noncanonical NLRP3 pathways[J]. Eur J Immunol, 2015, 45:2758-2761.
[41] Lee GS, Subramanian N, Kim AI, et al. The cal-cium-sensing receptor regulates the NLRP3 inflammasome through Ca2+ and cAMP[J]. Nature, 2012, 492:123-127.
[42] Horng T. Calcium signaling and mitochondrial destabiliza-tion in the triggering of the NLRP3 inflammasome[J]. Trends Immunol, 2014, 35:253-261.
[43] Rossol M, Pierer M, Raulien N, et al. Extracellular Ca2+ is a danger signal activating the NLRP3 inflammasome through G protein-coupled calcium sensing receptors[J]. Nat Commun, 2012, 3:1329.
[44] Misawa T, Takahama M, Kozaki T, et al. Micro-tubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome[J]. Nat Immunol, 2013, 14:454-460.
[45] Zhou RB, Yazdi AS, Menu P, et al. A role for mitochondria in NLRP3 inflammasome activation[J]. Nature, 2011, 469:221-225.
[46] Subramanian N, Natarajan K, Clatworthy MR, et al. The adaptor MAVS promotes NLRP3 mitochondrial localization and inflammasome activation[J]. Cell, 2013, 153:348-361.
[47] Park S, Juliana C, Hong S, et al. The mitochondrial anti-viral protein MAVS associates with NLRP3 and regulates its inflammasome activity[J]. J Immunol, 2013, 191:4358-4366.
[48] O'Neill LA. Cardiolipin and the Nlrp3 inflammasome[J]. Cell Metab, 2013, 18:610-612.
[49] Iyer SS, He Q, Janczy JR, et al. Mitochondrial cardiolipin is required for Nlrp3 inflammasome activation[J]. Immunity, 2013, 39:311-323.
[50] Saitoh T, Fujita N, Jang MH, et al. Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1β pro-duction[J]. Nature, 2008, 456:264-268.
[51] Nakahira K, Haspel JA, Rathinam VA, et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome[J]. Nat Immunol, 2011, 12:222-230.
[52] Lupfer C, Thomas PG, Anand PK, et al. Receptor interact-ing protein kinase 2-mediated mitophagy regulates inflam-masome activation during virus infection[J]. Nat Immunol, 2013, 14:480-488.
[53] Zhong ZY, Umemura A, Sanchez-Lopez E, et al. NF-κB restricts inflammasome activation via elimination of damaged mitochondria[J]. Cell, 2016, 164:896-910.
[54] Park S, Won JH, Hwang I, et al. Defective mitochondrial fission augments NLRP3 inflammasome activation[J]. Sci Rep, 2015, 5:15489.
[55] Ichinohe T, Yamazaki T, Koshiba T, et al. Mitochondrial protein mitofusin 2 is required for NLRP3 inflammasome activation after RNA virus infection[J]. Proc Natl Acad Sci U S A, 2013, 110:17963-17968.
[56] Rayamajhi M, Miao EA. The RIP1-RIP3 complex initiates mitochondrial fission to fuel NLRP3[J]. Nat Immunol, 2014, 15:1100-1102.
[57] Wang XQ, Jiang W, Yan YQ, et al. RNA viruses promote activation of the NLRP3 inflammasome through a RIP1-RIP3-DRP1 signaling pathway[J]. Nat Immunol, 2014, 15:1126-1133.
[58] Li Y, Zhou ZH, Chen MH, et al. Inhibition of mitochon-drial fission and NOX2 expression prevent NLRP3 inflammasome activation in endothelium:the role of corosolic acid action in the amelioration of endothelial dysfunction[J]. Antioxid Redox Signal, 2016, 24:893-908.
[59] Shimada K, Crother TR, Karlin J, et al. Oxidized mitochon-drial DNA activates the NLRP3 inflammasome during apop-tosis[J]. Immunity, 2012, 36:401-414.
[60] Bauernfeind F, Bartok E, Rieger A, et al. Cutting edge:reactive oxygen species inhibitors block priming, but not activation, of the NLRP3 inflammasome[J]. J Immunol, 2011, 187:613-617.
[61] Lamkanfi M, Dixit VM. Inflammasomes and their roles in health and disease[J]. Annu Rev Cell Dev Biol, 2012, 28:137-161.
[62] Cassel SL, Eisenbarth SC, Iyer SS, et al. The Nalp3 inflammasome is essential for the development of silicosis[J]. Proc Natl Acad Sci U S A, 2008, 105:9035-9040.
[63] Gris D, Ye ZM, Iocca HA, et al. NLRP3 plays a critical role in the development of experimental autoimmune enceph-alomyelitis by mediating Th1 and Th17 responses[J]. J Immunol, 2010, 185:974-981.
[64] Guarda G, Dostert C, Staehli F, et al. T cells dampen innate immune responses through inhibition of NLRP1 and NLRP3 inflammasomes[J]. Nature, 2009, 460:269-273.
[65] Yao Y, Vent-Schmidt J, McGeough MD, et al. Tr1 Cells, but not Foxp3+ regulatory T cells, suppress NLRP3 inflam-masome activation via an IL-10-dependent mechanism[J]. J Immunol, 2015, 195:488-497.
[66] Gurung P, Li BF, Subbarao Malireddi RK, et al. Chronic TLR stimulation controls NLRP3 inflammasome activation through IL-10 mediated regulation of NLRP3 expression and caspase-8 activation[J]. Sci Rep, 2015, 5:14488.
[67] Chow MT, Duret H, Andrews DM, et al. Type I NKT-cell-mediated TNF-α is a positive regulator of NLRP3 inflammasome priming[J]. Eur J Immunol, 2014, 44:2111-2120.
[68] Lamkanfi M, Mueller JL, Vitari AC, et al. Glyburide in-hibits the cryopyrin/Nalp3 inflammasome[J]. J Cell Biol, 2009, 187:61-70.
[69] Coll RC, Robertson AA, Chae JJ, et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases[J]. Nat Med, 2015, 21:248-255.
[70] He Y, Varadarajan S, Muñoz-Planillo R, et al. 3,4-Methyl-enedioxy-β-nitrostyrene inhibits NLRP3 inflammasome activation by blocking assembly of the inflammasome[J]. J Biol Chem, 2014, 289:1142-1150.
[71] Maier NK, Crown D, Liu J, et al. Arsenic trioxide and other arsenical compounds inhibit the NLRP1, NLRP3, and NAIP5/NLRC4 inflammasomes[J]. J Immunol, 2014, 192:763-770.
[72] Liu W, Guo WJ, Wu J, et al. A novel benzo[d]imidazole derivate prevents the development of dextran sulfate so-dium-induced murine experimental colitis via inhibition of NLRP3 inflammasome[J]. Biochem Pharmacol, 2013, 85:1504-1512.
[73] Guo WJ, Sun Y, Liu W, et al. Small molecule-driven mitophagy-mediated NLRP3 inflammasome inhibition is responsible for the prevention of colitis-associated cancer[J]. Autophagy, 2014, 10:972-985.
[74] Wang XQ, Wang SY, Hu CH, et al. A new pharmacological effect of levornidazole:inhibition of NLRP3 inflammasome activation[J]. Biochem Pharmacol, 2015, 97:178-188.
[75] Bruchard M, Mignot G, Derangère V, et al. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth[J]. Nat Med, 2013, 19:57-64.
[76] Paugh SW, Bonten EJ, Savic D, et al. NALP3 inflam-masome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells[J]. Nat Genet, 2015, 47:607-614.
[77] Shao BZ, Xu ZQ, Han BZ, et al. NLRP3 inflammasome and its inhibitors:a review[J]. Front Pharmacol, 2015, 6:262.